Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

Inclusion Criteria: * Able and willing to give written informed consent and participate in the study before any study procedure. * Age ≥ 18 years. * Understanding and able to write in Dutch or French. * Diagnosis of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for rheumatoid arthritis. * Previous response to rituximab, defined as a minimum of one successful rituximab cycle (= a moderate/good EULAR response 16 weeks after the first administration of rituximab). * Current treatment with rituximab. * Need for a subsequent rituximab cycle according to the Belgian reimbursement criteria for the use of rituximab in rheumatoid arthritis (DAS28 score ≥3.2). * Stable dose of methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (DMARDs) 4 weeks prior to baseline. Exclusion Criteria: * Current treatment with another biological DMARD than rituximab. * Current treatment with a targeted synthetic DMARD. * Pregnancy or pregnancy wish. * Presence of an absolute contraindication to treatment with rituximab, according to the label of rituximab and according to medical judgement.